Concepedia
Statistics
Publications
18
Citations
4.1K
H-Index
16
Active since
1993
Affiliations
Bristol-Myers Squibb (United States)(Current)
Seagen (United States)
Bristol-Myers Squibb (Germany)
Dana F. Chace is an author at Bristol-Myers Squibb (United States) specializing in medicine, immunology, and immunotherapy.
Top concepts
MedicineImmunologyImmunotherapyCancer ResearchPathologyCell BiologyTumor BiologyPharmacologyTumor ImmunityAntibody Engineering
Publications per year
1993–2004
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Kevin J. Hamblett, Peter D. Senter, Dana F. Chace et al. · Clinical Cancer Research · 2004 · 1.2K citations
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Svetlana O. Doronina, Brian E. Toki, Michael Torgov et al. · Nature Biotechnology · 2003 · 1.2K citations
Cancer Therapy, Polymer-drug Conjugate, Medicine +8
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
Joseph A. Francisco, Charles G. Cerveny, Damon L. Meyer et al. · Blood · 2003 · 907 citations
The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
Alan F. Wahl, Kerry Klussman, Jennifer Thompson et al. · PubMed · 2002 · 212 citations
Antitumor Activity, Dna Fragmentation, Immunology +18
Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates
Che‐Leung Law, Charles G. Cerveny, Kristine A. Gordon et al. · Clinical Cancer Research · 2004 · 116 citations
1–5 of 18